Usp5 KD improved apoptotic activity in both mutant and non-mutant BRAF melanoma, suggesting that Usp5 inhibitors would be useful in a broader patient population, including those that are candidates for other therapies [MEK inhibitor, immune-regulators (ipilimumab, IFN-α) DNA-damaging chemo-therapies]. The gene discussed is BRAF; the disease is melanoma.